Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Operating Income (2016 - 2025)

Historic Operating Income for Marker Therapeutics (MRKR) over the last 10 years, with Q3 2025 value amounting to -$2.1 million.

  • Marker Therapeutics' Operating Income rose 1096.5% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.9 million, marking a year-over-year decrease of 4583.83%. This contributed to the annual value of -$11.1 million for FY2024, which is 2374.95% up from last year.
  • Per Marker Therapeutics' latest filing, its Operating Income stood at -$2.1 million for Q3 2025, which was up 1096.5% from -$4.3 million recorded in Q2 2025.
  • In the past 5 years, Marker Therapeutics' Operating Income registered a high of -$2.1 million during Q3 2025, and its lowest value of -$9.8 million during Q1 2022.
  • For the 4-year period, Marker Therapeutics' Operating Income averaged around -$4.0 million, with its median value being -$3.9 million (2024).
  • As far as peak fluctuations go, Marker Therapeutics' Operating Income soared by 5600.21% in 2023, and later crashed by 8461.49% in 2025.
  • Over the past 4 years, Marker Therapeutics' Operating Income (Quarter) stood at -$3.0 million in 2022, then grew by 3.32% to -$2.9 million in 2023, then tumbled by 31.44% to -$3.9 million in 2024, then surged by 44.66% to -$2.1 million in 2025.
  • Its Operating Income stands at -$2.1 million for Q3 2025, versus -$4.3 million for Q2 2025 and -$4.6 million for Q1 2025.